Is intrathecal zorevunersen, an antisense oligonucleotide that upregulates NaV1.1 sodium channels, safe and effective in reducing seizures in children and adolescents with Dravet syndrome?
Can eslicarbazepine acetate prevent the development of post-stroke epilepsy in patients at high risk after acute stroke?
BIA-2093-213
Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial
Lancet Neurology · 2026
Bottom Line: Eslicarbazepine acetate did not significantly reduce the composite endpoint of first unprovoked seizure, death, or treatment discontinuation compared to placebo in post-stroke patients (28% vs 37%, OR 0.66, p=0.37). The trial was underpowered due to slow recruitment and COVID-19 disruptions but demonstrates the feasibility of conducting antiepileptogenesis trials.